Impact of Tea Tree Oil on dry eye treatment

Clinical trial comparing the effects of Tea Tree Oil and artificial tear and betamethasone drops on dry eye symptoms after phacoemulsification cataract surgery

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013111313567N5

Enrollment

Registered

2015-06-21

Start date

2015-06-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye syndrome. Other disorders of lacrimal gland

Interventions

Intervention 1: Intervention group: The first patient with a unique code (1) be given package A (i.e.Eyesol Ophthalmic cleansing shampoo containing Tea tree oil 5% plus Betamethasone Eye Drops 0.1% p

Treatment - Drugs

Placebo

Intervention group: The first patient with a unique code (1) be given package A (i.e.Eyesol Ophthalmic cleansing shampoo containing Tea tree oil 5% plus Betamethasone Eye Drops 0.1% plus Artelac Eye

Control group: The second patient with a unique code (2) be given package B (i.e.Eyesol Ophthalmic cleansing shampoo without Tea tree oil plus Betamethasone Eye Drops 0.1% plus Artelac Eye Drops). Pa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The Inclusion criteria: Dry-eye symptoms following Phacoemulsification Cataract Surgery that have not improved after 1 month with conventional treatments(artificial tear and betamethasone 0.1% drops); Index of 30 or more from the Ocular Surface Disease Questionnaire; The Schirmer test of 10 millimeter or less; The Tear Break up Times of 7 seconds or less; Lack of eye trauma; The absence of uveitis. Exclusion criteria: Surgery on eyes including Surgical Correction of Refractive Errors; Using contact lenses; Systemic diseases which cause dry eye such as Sjogren ,Diabetic Retinopathy and end organ damage disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Moisture eye. Timepoint: Before intervention-one month after treatment. Method of measurement: Schirmer Test -Millimeters.;Eye problems in performing daily. Timepoint: Before intervention-one month after treatment. Method of measurement: Ocular Surface Disease Index Questionnaire.;Tear break up time. Timepoint: Before intervention-one month after treatment. Method of measurement: Measured in seconds -With timer and Slit Lamp.;Visual acuity. Timepoint: Before intervention-one month after treatment. Method of measurement: Snelen chart.;The number of demodex of 4 eyelashes of each eye. Timepoint: Before intervention-one month after treatment. Method of measurement: Microscopic demodex examination.;Tear Osmolarity. Timepoint: Before intervention-one month after treatment. Method of measurement: Tearlab osmometer.	—

Measure

Time frame

Moisture eye. Timepoint: Before intervention-one month after treatment. Method of measurement: Schirmer Test -Millimeters.;Eye problems in performing daily. Timepoint: Before intervention-one month after treatment. Method of measurement: Ocular Surface Disease Index Questionnaire.;Tear break up time. Timepoint: Before intervention-one month after treatment. Method of measurement: Measured in seconds -With timer and Slit Lamp.;Visual acuity. Timepoint: Before intervention-one month after treatment. Method of measurement: Snelen chart.;The number of demodex of 4 eyelashes of each eye. Timepoint: Before intervention-one month after treatment. Method of measurement: Microscopic demodex examination.;Tear Osmolarity. Timepoint: Before intervention-one month after treatment. Method of measurement: Tearlab osmometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Mohammadpour

Tehran University of Medical Sciences

MAHAMMADPOUR@yahoo.com+98 21 5542 1006

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026